Three Targets, One CAR T Therapy
A first-in-human phase I study tested rapidly manufactured CAR-T cells directed at three B-cell antigens in relapsed or refractory malignancies.
TL;DR
- The phase I study tested CAR-T cells targeting CD19, CD20 and CD22 in patients with relapsed or refractory B-cell malignancies.
- Sixteen patients received treatment; the reported overall response rate was 50%, and 38% had complete responses.
- The study was small and included different diseases, so larger studies are needed to assess efficacy and safety.
The first-in-human phase I study evaluated a trispecific CAR-T product directed at CD19, CD20 and CD22. The Medicine Maker reports that the study enrolled 18 people with relapsed or refractory B-cell malignancies, and 16 received treatment. [1] [2]
The publication reports a 50% overall response rate among treated patients, with complete responses in 38%. In the subgroup with B-cell non-Hodgkin lymphoma, five of six patients achieved complete remission; four of those five remained in remission beyond one year. [1] [2]
The cells were produced using point-of-care manufacturing, with a median manufacturing time of 7 days and successful production for 16 of 17 patients for whom manufacturing was attempted. The report also describes no severe cytokine release syndrome, dose-limiting toxicities or immune effector cell-associated neurotoxicity syndrome in this small cohort. [1] [2]
The population combined several disease types and was limited in size, so the results do not establish comparative benefit or a broadly applicable safety profile. The researchers identify larger studies as necessary; the early findings leave open how outcomes will vary by disease and patient characteristics. [1] [2]
Why it matters
The study brings together multi-antigen targeting and faster, point-of-care cell manufacturing, two approaches intended to address antigen escape and production delays. Its small phase I cohort makes the findings an early clinical signal rather than confirmation of benefit.
Editor's note
TODO-review: Confirm detailed safety and subgroup figures against the full journal article; publisher page access was restricted during preparation. No treatment guidance is implied.